Letter by Mbmaurya and Gupta on “Cost-Effectiveness of Physical Therapist Treatment in Addition to Usual Podiatry Management of Plantar Heel Pain: Economic Evaluation of a Randomized Clinical Trial.” McClinton SM, Heiderscheit BC, Flynn TW, Pinto D. Phys Ther . 2025;105:pzaf119. http://doi.org/10.1093/Ptj/pzaf119

We read with immense interest the economic assessment by McClinton et al examining the cost-effectiveness of adding physical therapist–directed treatment to usual chiropody management for plantar heel pain.1 The authors deliver an important contribution by addressing the economic consequences of multidisciplinary management for a highly dominant musculoskeletal condition linked with significant functional limitation and health care application. The combination of cost-effectiveness study within randomized clinical trial methodology signifies a valuable advancement in directing value-based physical therapist practice. Nevertheless, numerous methodological and interpretative findings merit further discussion to reinforce translational and clinical relevance of the reported findings. First, even though the study establishes cost-effectiveness advantages linked with physical therapist intervention, the evaluation depends heavily on incremental cost-effectiveness ratios derived principally from health-related quality-of-life measures. While quality-adjusted life-year (QALY) calculations deliver standardized financial benchmarking, their findings in detecting clinically meaningful functional improvements in people with plantar heel pain may be limited. Plantar heel pain is strongly depicted by activity-related pain, gait dysfunction, and participation restriction rather than general health-related quality-of-life impairment.2 Accordingly, economic conclusions derived chiefly from QALY-based outcomes may misjudge condition-specific functional benefits attributable to physical therapist interventions. Integrating condition-specific functional measures such as the Foot Function Index or activity participation scales into cost-utility pattern could deliver a more clinically meaningful depiction of therapeutic value.